Berenberg Bank Remains Bullish on AstraZeneca PLC (AZN) - Here's Why

AstraZeneca PLC (NASDAQ:AZN) is one of the best performing pharma stocks in 2025. On January 7, Berenberg Bank reiterated a Buy rating on AstraZeneca PLC (NASDAQ:AZN) with a price target of $95. The rating update came after AstraZeneca PLC (NASDAQ:AZN) announced positive full results from the Phase III TULIP-SC trial on December 6, reporting that the subcutaneous administration of Saphnelo (anifrolumab) exhibited a clinically meaningful and statistically significant drop in disease activity compared to placebo in patients with systemic lupus erythematosus (SLE).

56.2% of patients who received Saphnelo in the TULIP-SC full analysis showed disease activity reduction at Week 52 compared to 37.1% receiving placebo, as measured by the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA), with the results consistent with those from previous trials.

Management further reported that the safety profile observed in the TULIP-SC trial was also consistent with Saphnelo’s known clinical profile, administered as an intravenous (IV) infusion. According to AstraZeneca PLC (NASDAQ:AZN), the full results corroborated the findings from the interim analysis, which was statistically significant.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.